Injection of MSC303
Phase 2Small molecule
Injection of MSC303 is one of 7 small molecule programs targeting Glomerular Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Glomerular Disease
#DrugCompanyPhaseTrials
1Vanrafia
NovartisPhase 2
Filspari
TTravere Therapeutics, Inc.
Phase 2
Medrol
PfizerPreclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Rayos
RRoxane Laboratories
Preclinical
Injection of MSC303
SShanghai Changzheng Hospital
Phase 2
Methylprednisolone, Prednisone
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Injection of MSC303. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Changzheng Hospital